Sustained Delivery of IL-1Ra from PF127-Gel Reduces Hyperglycemia in Diabetic GK-Rats

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Akash, Muhammad Sajid Hamid ^a,b   Rehman, Kanwal ^a   Sun, Hongying ^a   Chen, Shuqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 16; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELLULAR SECRETION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INSULIN SENSITIVITY; KIDNEY FUNCTION; MACROPHAGE FUNCTION; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; RAT; SKIN FUNCTION; SUSTAINED DRUG RELEASE; TREATMENT DURATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GELS; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; ISLETS OF LANGERHANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; POLOXAMER; RATS; SKIN;

EID: 84873668406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055925     Document Type: Article

References (65)

1. Brownlee M, (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
2. Creager MA, Luscher TF, Cosentino F, Beckman JA, (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 108: 1527-1532.
3. Donath MY, Ellingsgaard H, Schumann DM, Perren A, Faulenbach M, et al. (2008) Islet inflammation in type 2 diabetes: From metabolic stress to therapy. Diabetes Care 31: S161-S164.
4. Dinarello CA, (2011) Blocking interleukin-1β in acute and chronic autoinflammaotry diseases. J Intern Med 269: 16-28.
5. Donath MY, Shoelson SE, (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11: 98-107.
6. Schroder K, Zhou R, Tschopp J, (2010) The NLRP3 inflammasome: A sensor for metabolic danger? Science 327: 296-300.
7. Aggeli IK, Theofilatos D, Beis I, Gaitanaki C, (2011) Insulin induced oxidative stress upregulates heme oxygenase-1 via diverse signaling cascades in the C2 skeletal myoblast cell line. Endocrinology 152: 1274-1283.
8. Akash MSH, Rehman K, Rasool F, Sethi A, Abrar MA, et al. (2011) Alternate therapy of Type 2 diabetes mellitus (T2DM) with Nigella (Ranunculaceae). J Med Plants Res 5: 6885-6889.
9. Akash MSH, Shen Q, Rehman K, Chen S, (2012) Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 101: 1647-1658.
10. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
11. Wellen KE, Hotamisligil GS, (2005) Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119.
12. Navab M, Gharavi N, Watson AD, (2008) Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care 11: 459-464.
13. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, et al. (2007) Increased Number of Islet Associated Macrophages in Type 2 Diabetes. Diabetes 56: 2356-2370.
14. Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, et al. (2010) Toll-like receptor 2-deficient mice are protected from insulin resistance and β cell dysfunction induced by a high-fat diet. Diabetologia 53: 1795-1806.
15. Homo-Delarche F, Calderari S, Irminger JC, Gangnerau MN, Coulaud J, et al. (2006) Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 55: 1625-1633.
16. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, et al. (2004) Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc Natl Acad Sci USA 101: 8138-8143.
17. Boni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, et al. (2009) Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology. 150: 5218-5229.
18. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, et al. (2007) Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526.
19. Ehses JA, Lacraz G, Giroix M, Schmidlin F, Coulaud J, et al. (2009) IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 106: 13998-14003.
20. Dinarello CA, (1996) Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
21. Dinarello CA, (2000) The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343: 732-4.
22. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K, (2008) The Anti-inflammatory Cytokine Interleukin-1 Receptor Antagonist Protects from High-Fat Diet-Induced Hyperglycemia. Endocrinology 149: 2208-2218.
23. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, et al. (2002) Glucose-induced β-cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110: 851-860.
24. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, et al. (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32: 1663-1668.
25. Dinarello CA, (2004) Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4: 378-385.
26. Akash MSH, Rehman K, Li N, Gao JQ, Sun H, et al. (2012) Sustained delivery of IL-1Ra from Pluronic F127-based thermosensitive gel prolongs its therapeutic potentials. Pharm Res. 29: 3475-3485.
27. Wang PL, Johnston TP, (1993) Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol 47: 183-189.
28. Katakam M, Bell LN, Banga AK, (1995) Effect of surfactants on the physical stability of rhGH. J Pharm Sci 84: 713-716.
29. Das N, Madan P, Lin S, (2012) Statistical optimization of insulin-loaded Pluronic F-127 gels for buccal delivery of basal insulin. Pharm Dev Technol 17: 363-374.
30. Stratton LP, Dong A, Manning MC, Carpenter JF, (1997) Drug delivery matrix containing native protein precipitates suspended in a polomaxamer gel. J Pharm Sci 86: 1006-1010.
31. Johnston TP, Punjabi MA, Froelich CJ, (1992) Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res 9: 425-434.
32. Barichello JM, Morishita M, Takayama K, Nagai T, (1999) Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm 184: 189-198.
33. Liu Y, Lu WL, Wang JC, Zhang X, Zhang H, et al. (2007) Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization. J Control Release 117: 387-395.
34. Chaibva FA, Walker RB, (2007) The comparison of in vitro release methods for the evaluation of oxytocin release from pluronic® f127 parenteral formulations. Dissolution Technologies 14: 15-26.
35. Hiwale P, Lampis S, Conti G, Caddeo C, Murgia S, et al. (2011) In vitro release of lysozyme from gelatin microspheres: effect of cross-linking agents and thermoreversible gel as suspending medium. Biomacromolecules 12: 3186-3193.
36. Portha B, Lacraz G, Kergoat M, Homo-Delarche F, Giroix MH, et al. (2009) The GK rat beta-cell: A prototype for the diseased human beta-cell in type 2 diabetes? Mol Cell Endocrinol 297: 73-85.
37. Portha B, (2005) Programmed disorders of beta-cell development and function as one cause for type 2 diabetes? The GK rat paradigm. Diab Metab Res Rev 21: 495-504.
38. Movassat J, Bailbé D, Lubrano-Berthelier C, Picarel-Blanchot F, Bertin E, et al. (2008) Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion. Am J Physiol Endocrinol Metab 294: E168-E175.
39. de Assis AM, Rieger DK, Longoni A, Battu C, Raymundi S, et al. (2009) High fat and highly thermolyzed fat diets promote insulin resistance and increase DNA damage in rats. Exp Biol Med (Maywood) 234: 1296-1304.
40. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
41. Caro JF, (1991) Insulin resistance in obese and non obese man. J Clin Endocrinol Metab 73: 691-695.
42. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, et al. (2000) Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 86: 2402-2410.
43. Akash MSH, Rehman K, Chen S. (2012) Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. DOI: 10.1002/jcb.24402.
44. Akash MSH, Rehman K, Sun H, Chen S. (2013) Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-Rats. Eur J Pharmacol. DOI: 10.1016/j.ejphar.2013.01.008.
45. Song Y, Manson JE, Tinker L, Howard BV, Kuller LH, et al. (2007) Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care 30: 1747-1752.
46. Boyko EJ, Jensen CC, (2007) Do we know what homeostasis model assessment measures? If not, does it matter? Diabetes Care 30: 2729-36.
47. Wallis RH, Wallace KJ, Collins SC, Mc Ateer M, Argoud K, et al. (2004) Enhanced insulin secretion and cholesterol metabolism in congenic strains of the spontaneously diabetic (Type 2) Goto Kakizaki rat are controlled by independent genetic loci in rat chromosome 8. Diabetologia 47: 1096-1106.
48. Antuna-Puente B, Faraj M, Karelis AD, Garrel D, Prud'homme D, et al. (2008) HOMA or QUICKI: is it useful to test the reproducibility of formulas? Diabetes Metab 34: 294-296.
49. Gaisano HY, Ostenson CG, Sheu L, Wheeler MB, Efendic S, (2002) Abnormal expression of pancreatic islet exocytotic soluble N-ethylmaleimide-sensitive factor attachment protein receptors in Goto-Kakizaki rats is partially restored by phlorizin treatment and accentuated by high glucose treatment. Endocrinology 143: 4218-4226.
50. Briaud I, Kelpe CL, Johnson LM, Tran PO, Poitout V, (2002) Differential effects of hyperlipidemia on insulin secretion in islets of langerhans from hyperglycemic versus normoglycemic rats. Diabetes 51: 662-668.
51. Argoud K, Wilder SP, McAteer MA, Bihoreau MT, Ouali F, et al. (2006) Genetic control of plasma lipid levels in a cross derived from normoglycaemic Brown Norway and spontaneously diabetic Goto-Kakizaki rats. Diabetologia 49: 2679-2688.
52. Perone RD, Madias NE, Levey AS, (1992) Serum creatinine as an index of renal function. New insights into old concepts. Clin Chem 38: 1933-1953.
53. Shinde UA, Goyal RK, (2003) Effect of chromium picolinate on histopathological alterations in STZ and neonatal STZ diabetic rats. J Cell Mol Med 7: 322-329.
54. Murugan P, Pari L, (2007) Influence of tetrahydrocurcumin on hepatic and renal functional markers and protein levels in experimental type 2 diabetic rats. Basic Clin Pharmacol Toxicol 101: 241-245.
55. Mansour HA, Newairy AA, (2000) Amelioration of impaired renal function associated with diabetes by Balanites aegyptiaca fruits in streptozotocin-induced diabetic rats. J Med Res Inst 21: 115-125.
56. Kaleem M, Medha P, Ahmed Q U, Asif M, Bano B, (2008) Beneficial effects of Annona squamosa extract in streptozotocin-induced diabetic rats. Singapore Med J 49: 800-804.
57. Gomes MB, Lucctetti MR, Gonacalvez MFR, (1997) Influence of first morning urine volume, fasting blood and glycosylated Hb on first morning urine albumin excretion. Braz J Med Biol Res 30: 191-196.
58. Pawluczyk IZ, Harris KP, (1997) Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis. J Am Soc Nephrol 8: 1525-1536.
59. Schrijvers BF, De Vriese AS, Van de Voorde J, Rasch R, et al. (2004) Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes. Nephrol Dial Transplant 19: 1092-1097.
60. Ohta T, Miyajima K, Komuro G, Furukawa N, Yonemori F, (2003) Antidiabetic effect of chronic administration of JTT-608, a new hypoglycemic agent, in diabetic Goto-Kakizaki rats. Eur J Pharmacol 476: 159-166.
61. de Zeeuw D, Remuzzi G, Parving H, (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320.
62. Sohn EJ, Kim C-S, Kim YS, Jung DH, Jang DS, et al. (2007) Effects of magnolol (5,5 ′-diallyl-2,2 ′-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. Life Sci 80: 468-475.
63. Fu J, Li Y, Wang L, Gao B, Zhang N, et al. (2009) Paeoniflorin prevents diabetic nephropathy in rats. Comp Med 59: 557-566.
64. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA, (2009) Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology (Bethesda) 24: 325-331.
65. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG, (2009) Islet-associated macrophages in type 2 diabetes. Diabetologia 52: 1686-1688.